Clinical efficacy of perampanel monotherapy in children with focal epilepsy_Journal of Epilepsy

Authors：

CHEN Lilan ,  WANG Jianbiao , ZHOU Yineng , SUN Mingxia

Department of Pediatric Neurology, Affiliated Children's Hospital of Jiangnan University (Wuxi Children’s Hospital), Wuxi 214000, China;

Corresponding author：

WANG Jianbiao, Email: wjb00883@sina.com

Keywords：

Perampanel; Levetiracetam; Focal epilepsy

DOI：

10.7507/2096-0247.202303002

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the efficacy and safety of Perampanel (PER) monotherapy in children with focal epilepsy. Methods Forty-six children with focal epilepsy who were newly diagnosed in the Department of Neurology of Wuxi Children's Hospital and had not used anti-seizure medications during January 2021 to June 2022 were selected, including 24 males and 22 females, with an average age of (7.2 ± 2.4) years old. Mono-therapy of PER as the PER group (23 cases), mono-therapy of Levetiracetam (LEV) as the LEV group (23 cases). Compare the clinical efficacy and adverse reactions between the two groups. Result The total effective rate was 87.0% (20/23) in PER group and 73.9% (17/23) in LEV group after 3 months of treatment (P<0.05); the total effective rate in the PER group was 78.3% (18/23), and 60.9% (14/23) in the LEV group after 6 months of treatment (P<0.05). The differences were statistically significant. In the PER group, 2 children had adverse reactions, 1 case was lethargic, and 1 case was dizziness. By temporarily reducing the drug dose and slowing the rate of dosing, the adverse reactions disappeared. In LEV group, 3 children had adverse reactions, all of who were irritable in varying degrees. By slowing down the rate of drug addition, 2 children’s symptoms disappeared and 1 child's symptoms relieved during 3 ~ 6 months. Conclusion The new anti-seizure medication — PER has a better anti-epileptic effect on focal epilepsy, which is better than LEV. The adverse reactions of both drugs are less and mild, and can be selected according to clinical conditions.

Citation： CHEN Lilan, WANG Jianbiao, ZHOU Yineng, SUN Mingxia. Clinical efficacy of perampanel monotherapy in children with focal epilepsy. Journal of Epilepsy, 2023, 9(3): 192-194. doi: 10.7507/2096-0247.202303002 Copy

1.	Devinsky O, Vezzani A, O'Brien TJ, et al. Epilepsy. Nature Reviews Disease Primers, 2018, 1: 27-31.
2.	Melchers NV, Mollenkopf S, Colebunders R, et al. Burden of onchocerciasis-associated epilepsy: first estimates and research priorities. Infectious Diseases of Poverty, 2018, 7(1): 55-58.
3.	Carlson J M, Miller P A. Family burden, child disability, and the adjustment of mothers caring for children with epilepsy: Role of social support and coping. Epilepsy & Behavior, 2017, 68: 168-173.
4.	Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia, 2011, 52(7): 1331-1340.
5.	Jerry S, Tatum M, Leslie R. New drug classes for the treatment of partial onset epilepsy: focus on perampanel. Therapeutics & Clinical Risk Management, 2013, 56: 156-162.
6.	卫材（中国）药业有限公司. 吡仑帕奈药品说明书. 2021.
7.	Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia, 2017, 58(4): 512-521.
8.	中国抗癫痫协会. 临床诊疗指南: 癫痫病分册. 人民卫生出版社, 2015.
9.	Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Currents, 2011, 11(2): 56-63.
10.	Potschka H. Perampanel: does it have broad-spectrum potential? Epilepsia, 2019, 60（Suppl 1）: 22-36.
11.	Satlin A, Kramer LD, Laurenza A. Development of perampanel in epilepsy. Acta Neurol Scand Suppl, 2013, 127(s197): 3-8.
12.	史卫忠, 徐春敏, 韩容. 新型口服抗癫痫药吡仑帕奈. 药品评价, 2012, (29): 5-8.
13.	向魏坪. 新型抗癫痫药物在儿科人群中药代动力学研究进展. 中国临床药理学杂志, 2016, 32(24): 2323-2325.
14.	杜玲玲, 徐佳骏, 崔岚. 选择性AMPA受体拮抗药吡仑帕奈概述. 中国药师, 2013, (8): 3-5.
15.	麦子荆, 崔晗, 樊彩芳, 等. 吡仑帕奈治疗儿童癫痫局灶性发作的疗效及安全性. 中国实用神经疾病杂志, 2022, 15(2): 25-29.

1. Devinsky O, Vezzani A, O'Brien TJ, et al. Epilepsy. Nature Reviews Disease Primers, 2018, 1: 27-31.
2. Melchers NV, Mollenkopf S, Colebunders R, et al. Burden of onchocerciasis-associated epilepsy: first estimates and research priorities. Infectious Diseases of Poverty, 2018, 7(1): 55-58.
3. Carlson J M, Miller P A. Family burden, child disability, and the adjustment of mothers caring for children with epilepsy: Role of social support and coping. Epilepsy & Behavior, 2017, 68: 168-173.
4. Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia, 2011, 52(7): 1331-1340.
5. Jerry S, Tatum M, Leslie R. New drug classes for the treatment of partial onset epilepsy: focus on perampanel. Therapeutics & Clinical Risk Management, 2013, 56: 156-162.
6. 卫材（中国）药业有限公司. 吡仑帕奈药品说明书. 2021.
7. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia, 2017, 58(4): 512-521.
8. 中国抗癫痫协会. 临床诊疗指南: 癫痫病分册. 人民卫生出版社, 2015.
9. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Currents, 2011, 11(2): 56-63.
10. Potschka H. Perampanel: does it have broad-spectrum potential? Epilepsia, 2019, 60（Suppl 1）: 22-36.
11. Satlin A, Kramer LD, Laurenza A. Development of perampanel in epilepsy. Acta Neurol Scand Suppl, 2013, 127(s197): 3-8.
12. 史卫忠, 徐春敏, 韩容. 新型口服抗癫痫药吡仑帕奈. 药品评价, 2012, (29): 5-8.
13. 向魏坪. 新型抗癫痫药物在儿科人群中药代动力学研究进展. 中国临床药理学杂志, 2016, 32(24): 2323-2325.
14. 杜玲玲, 徐佳骏, 崔岚. 选择性AMPA受体拮抗药吡仑帕奈概述. 中国药师, 2013, (8): 3-5.
15. 麦子荆, 崔晗, 樊彩芳, 等. 吡仑帕奈治疗儿童癫痫局灶性发作的疗效及安全性. 中国实用神经疾病杂志, 2022, 15(2): 25-29.

Previous Article
Prognostic analysis of status epilepticus
Next Article
Secondary recurrence of central nervous system leukemia complicated with epilepsy in children: a case report and literature review

Journal of Epilepsy

Clinical efficacy of perampanel monotherapy in children with focal epilepsy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content